Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.9K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

471
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
471
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

518
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
518
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

445
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
445
Effects of EDTA on End-Point Detection Methods01:18

Effects of EDTA on End-Point Detection Methods

772
Different methods, such as visual observance of metal-ion indicators, spectroscopic techniques, and potentiometric methods, can determine the endpoint of an EDTA titration.
In the visual method, metal-ion indicators (metallochromic dyes), which have distinct colors in their free and complex forms, are added to the mixture to signal the titration's end point. They form stable complexes with metal ions, but these complexes are weaker than the corresponding metal–EDTA complexes. As a...
772

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic value of the Duke Activity Status Index for preoperative cardiac risk stratification: an international pooled cohort study.

EClinicalMedicine·2026
Same author

Perioperative Management: HeartMate 3 Left Ventricular Assist Devices in Non-Cardiac Surgery.

Journal of cardiothoracic and vascular anesthesia·2026
Same author

Frailty Status and Preoperative Cardiac Risk Stratification in Older Adults Undergoing Noncardiac Surgery: A Multicenter Prospective Cohort Study.

Journal of the American Heart Association·2026
Same author

Impact of Operator-Patient Sex Concordance on Patient Outcomes in Cardiac Electrophysiology Procedures for Atrial Fibrillation.

CJC open·2026
Same author

Transesophageal echocardiography and pulmonary artery catheter use and short-term outcomes in patients undergoing coronary artery bypass surgery: A multi-center retrospective study.

BMC cardiovascular disorders·2026
Same author

Predicting Days at Home after Elective Surgery for Gastrointestinal Cancer using HOMEDAYS: Prediction Model Development and Internal Validation.

Journal of the American College of Surgeons·2026

Related Experiment Video

Updated: Apr 15, 2026

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

1.8K

Tranexamic acid: a clinical review.

William Ng, Angela Jerath, Marcin Wąsowicz1

  • 1University of Toronto Department of Anesthesia, UHN Toronto General Hospital. marcin.wasowicz@uhn.ca.

Anaesthesiology Intensive Therapy
|March 24, 2015
PubMed
Summary

Antifibrinolytic agents like tranexamic acid (TXA) effectively reduce blood loss in various surgeries. This review guides physicians on TXA use, dosing, and safety, highlighting areas needing further research.

Keywords:
anesthesiaantifibrinolyticblood conservationtranexamic acid

More Related Videos

Author Spotlight: Developing a Safer and More Efficient Treatment Protocol for Wasting Marmoset Syndrome (WMS)
03:07

Author Spotlight: Developing a Safer and More Efficient Treatment Protocol for Wasting Marmoset Syndrome (WMS)

Published on: July 12, 2024

1.9K
Complete and Partial Aortic Occlusion for the Treatment of Hemorrhagic Shock in Swine
09:37

Complete and Partial Aortic Occlusion for the Treatment of Hemorrhagic Shock in Swine

Published on: August 24, 2018

11.1K

Related Experiment Videos

Last Updated: Apr 15, 2026

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

1.8K
Author Spotlight: Developing a Safer and More Efficient Treatment Protocol for Wasting Marmoset Syndrome (WMS)
03:07

Author Spotlight: Developing a Safer and More Efficient Treatment Protocol for Wasting Marmoset Syndrome (WMS)

Published on: July 12, 2024

1.9K
Complete and Partial Aortic Occlusion for the Treatment of Hemorrhagic Shock in Swine
09:37

Complete and Partial Aortic Occlusion for the Treatment of Hemorrhagic Shock in Swine

Published on: August 24, 2018

11.1K

Area of Science:

  • Pharmacology
  • Surgical Medicine
  • Critical Care

Background:

  • Blood loss and transfusions significantly increase patient morbidity and mortality.
  • Antifibrinolytic agents are proven to reduce blood loss across diverse surgical fields.
  • Tranexamic acid (TXA) is an increasingly utilized antifibrinolytic, contrasting with aprotinin.

Purpose of the Study:

  • To provide acute care physicians with evidence-based guidance on tranexamic acid (TXA) therapy.
  • To assist in developing optimal TXA dosing regimens while minimizing potential harm.
  • To elucidate the expanding clinical applications and remaining uncertainties surrounding TXA.

Main Methods:

  • Comprehensive review of existing clinical evidence on TXA efficacy and safety.
  • Analysis of TXA's mechanism of action as a synthetic lysine-analogue antifibrinolytic.
  • Synthesis of data to inform clinical decision-making for TXA administration.

Main Results:

  • TXA demonstrates efficacy in reducing blood loss in numerous surgical specialties.
  • Evidence supporting antifibrinolytic use has grown substantially over time.
  • TXA's application is expanding, necessitating a clear understanding of its benefits and risks.

Conclusions:

  • TXA is a valuable tool for managing blood loss in various clinical settings.
  • Further clinical trials are essential to address unanswered questions regarding TXA's safety profile.
  • Understanding TXA's broader effects, including thromboembolic risk and neurological impact, requires continued investigation.